Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
- Ronan Swords
- , Yesid Alvarado
- , Jorge Cortes
- , Francis J. GilesAffiliated withDepartment of Leukemia, The University of Texas M.D. Anderson Cancer Center Email author
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Chronic myeloid leukemia (CML) was the first human malignancy to be associated with a single genetic abnormality, characterized by a reciprocal translocation involving chromosomes 9 and 22 (the Philadelphia chromosome). The fusion gene that results (BCR-ABL) produces a constitutively activated tyrosine kinase that exists in different isoforms depending on BCR break-points. Imatinib mesylate is a highly selective inhibitor of this kinase, producing normal blood-counts in 98% of patients in chronic phase CML and disappearance of the Philadelphia chromosome in 86%. However, 17% of patients in the chronic phase will either relapse or develop resistance resulting mainly from one or more point mutations affecting at least 30 amino acids within the Abl kinase protein. This review focuses on the relevant biology of CML, imatinib mesylate resistance mechanisms, and the current status of the next generation of Bcr-Abl inhibitors.
- Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia
Current Hematologic Malignancy Reports
Volume 2, Issue 2 , pp 83-88
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links